NCT lookup

Inclusion Criteria:

* Parkinson\'s disease at the stage of L-dopa-induced severe motor and non-motor complications
* Men or women over 18 years old
* Parkinson\'s disease according to MDS criteria
* Severe motor complications including motor fluctuations with at least 2 hours of Off and 1 hour of dyskinesias uncontrolled by optimized oral drug therapy, i.e. with at least 5 doses of L-dopa and the addition or trial of a dopaminergic agonist (if tolerated) per os or by apomorphine pump
* The patient meets the criteria for a second-line invasive treatment such as deep brain stimulation (subthalamic or medial pallidum) or intrajejunal administration of levodopa gel (Duodopa®).
* Patients with a contraindication or who prefer this invasive therapeutic alternative to the other two existing and validated therapies (subthalamic stimulation or Duodopa®) because of its advantages: lower theoretical risk of intracerebroventricular delivery compared to subthalamic stimulation and better ergonomics than Duodopa®, but with the disadvantage of an as yet unproven benefit.
* Social security
* Able to provide free and informed consent to participate in research
* Patient willing to comply with all study procedures and duration
* Patient not planning to change lifestyle (nutritionally, physically or socially) during study participation

Exclusion Criteria:

* Over 75 years of age
* Subjects not receiving at least 5 doses per day of oral dopaminergic therapy
* Subject without a prior trial of an apomorphine pump (of lower risk); apomorphine pump treatment being a failure or a contraindication or refused by the patient
* Psychiatric history using the semi-structured psychiatric interview with DSM IV MINI: decompensated bipolar illness, psychotic state, current severe depression. Dysthymia and an isolated history of depression are not exclusion criteria.
* Patient with parkinsonian dementia (DSM IV and MDS criteria and MOCA score \< or equal to 22)
* Isolated patient, defined as the absence of a caregiver present at least 3 hours/day in the patient\'s home.
* History of a fall in the last 6 months and/or a score \>1 on items 2.12 (Walking and balance) and/or 3.12 (Postural stability) of the MDS-UPDRS scale
* Presence of another serious pathology threatening short- or medium-term vital prognosis, malnourished or cachectic patient.
* Hemostasis disorders
* Cardiac rhythm disorders and/or heart failure not controlled by treatment
* Uncontrolled blood pressure release
* Breastfeeding and pregnancy
* Women of childbearing age without effective contraception
* Contraindication to general anaesthesia
* Taking treatments containing guanethidine or related compounds or non-selective and selective monoamine oxidase A inhibitors (iproniazid, moclobemide, toloxatone)
* Neurosurgical contraindication (severe cerebral atrophy, brain tumor, infarction or other cerebral pathology, CSF flow disorder)
* Contraindication to abdominal placement of a subcutaneous pump and catheter that impairs healing and transcutaneous filling (e.g. major obesity, skin pathology, etc.).
* Contraindication to MRI (pacemaker, claustrophobia, etc.) and/or intolerance to gadolinium
* Active infectious pathology (including Covid-19)
* Immunologically deficient pathology likely to promote superinfection of equipment
* Patients under guardianship or trusteeship
* Patient already participating in another therapeutic trial using an investigational drug or in an exclusion period

• Lille, France